Revolution Medicines, Inc. $RVMD Stock: Robeco Institutional Asset Management B.V. Grows Position

Robeco Institutional Asset Management B.V. grew its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 439.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 22,319 shares of the company’s stock after acquiring an additional 18,179 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Revolution Medicines were worth $4,581,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Burkett Financial Services LLC purchased a new position in Revolution Medicines in the third quarter valued at approximately $27,000. Contravisory Investment Management Inc. acquired a new position in Revolution Medicines during the second quarter valued at approximately $32,000. Johnson Financial Group Inc. purchased a new stake in Revolution Medicines during the second quarter worth approximately $37,000. Silvant Capital Management LLC purchased a new stake in Revolution Medicines during the second quarter worth approximately $41,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in Revolution Medicines during the second quarter worth approximately $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Activity

In related news, insider Alan Sandler sold 6,309 shares of Revolution Medicines stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the sale, the insider owned 52,559 shares of the company’s stock, valued at $10,624,276.26. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Margaret Horn sold 4,967 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares in the company, valued at $29,822,243.20. This represents a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 290,991 shares of company stock worth $59,422,765 over the last three months. 7.60% of the stock is currently owned by corporate insiders.

Revolution Medicines Stock Down 0.4%

NASDAQ RVMD opened at $186.99 on Friday. The stock has a market cap of $40.08 billion, a PE ratio of -21.20 and a beta of 1.40. Revolution Medicines, Inc. has a fifty-two week low of $53.67 and a fifty-two week high of $224.31. The business has a 50 day moving average price of $201.70 and a two-hundred day moving average price of $176.65. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the business earned ($1.31) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -8.94 EPS for the current fiscal year.

Analyst Ratings Changes

RVMD has been the subject of several recent research reports. Sanford C. Bernstein increased their price objective on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Evercore restated an “outperform” rating and set a $320.00 target price on shares of Revolution Medicines in a report on Thursday, August 27th. UBS Group upped their price target on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Oppenheimer increased their price target on Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, William Blair started coverage on Revolution Medicines in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $242.90.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.